198 related articles for article (PubMed ID: 22297387)
21. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
[TBL] [Abstract][Full Text] [Related]
22. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.
Wang HH; Portincasa P; Mendez-Sanchez N; Uribe M; Wang DQ
Gastroenterology; 2008 Jun; 134(7):2101-10. PubMed ID: 18442485
[TBL] [Abstract][Full Text] [Related]
23. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
Davis HR; Veltri EP
J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
[TBL] [Abstract][Full Text] [Related]
24. The pharmacokinetics of ezetimibe.
Simard C; Turgeon J
Can J Clin Pharmacol; 2003; 10 Suppl A():13A-20A. PubMed ID: 14571304
[TBL] [Abstract][Full Text] [Related]
25. Caveolin-1 is not required for murine intestinal cholesterol transport.
Valasek MA; Weng J; Shaul PW; Anderson RG; Repa JJ
J Biol Chem; 2005 Jul; 280(30):28103-9. PubMed ID: 15919660
[TBL] [Abstract][Full Text] [Related]
26. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice.
Oswald S; Koll C; Siegmund W
J Pharm Sci; 2007 Dec; 96(12):3478-84. PubMed ID: 17828742
[TBL] [Abstract][Full Text] [Related]
27. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
28. [Ezetimibe--intestinal cholesterol absorbtion inhibitor].
Pikto-Pietkiewicz W; Pasierski T
Kardiol Pol; 2006 Dec; 64(12):1434-41. PubMed ID: 17206545
[No Abstract] [Full Text] [Related]
29. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
Genvigir FD; Rodrigues AC; Cerda A; Arazi SS; Willrich MA; Oliveira R; Hirata MH; Dorea EL; Bernik MM; Curi R; Hirata RD
Pharmacogenomics; 2010 Sep; 11(9):1235-46. PubMed ID: 20860464
[TBL] [Abstract][Full Text] [Related]
30. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption.
Hui DY; Labonté ED; Howles PN
Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G839-43. PubMed ID: 18276831
[TBL] [Abstract][Full Text] [Related]
31. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
Jia L; Betters JL; Yu L
Annu Rev Physiol; 2011; 73():239-59. PubMed ID: 20809793
[TBL] [Abstract][Full Text] [Related]
32. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
33. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Kosoglou T; Statkevich P; Johnson-Levonas AO; Paolini JF; Bergman AJ; Alton KB
Clin Pharmacokinet; 2005; 44(5):467-94. PubMed ID: 15871634
[TBL] [Abstract][Full Text] [Related]
34. Liver-specific induction of Abcg5 and Abcg8 stimulates reverse cholesterol transport in response to ezetimibe treatment.
Altemus JB; Patel SB; Sehayek E
Metabolism; 2014 Oct; 63(10):1334-41. PubMed ID: 25060694
[TBL] [Abstract][Full Text] [Related]
35. PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM; Lau JL; Alvarellos ML; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Jul; 25(7):363-76. PubMed ID: 25966836
[No Abstract] [Full Text] [Related]
36. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
Hill CR; Jamieson D; Thomas HD; Brown CD; Boddy AV; Veal GJ
Biochem Pharmacol; 2013 Jan; 85(1):29-37. PubMed ID: 23063411
[TBL] [Abstract][Full Text] [Related]
37. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
38. Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats.
Yamamoto T; Ito K; Honma M; Takada T; Suzuki H
Drug Metab Dispos; 2007 Sep; 35(9):1455-8. PubMed ID: 17567728
[TBL] [Abstract][Full Text] [Related]
39. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.
Altmann SW; Davis HR; Yao X; Laverty M; Compton DS; Zhu LJ; Crona JH; Caplen MA; Hoos LM; Tetzloff G; Priestley T; Burnett DA; Strader CD; Graziano MP
Biochim Biophys Acta; 2002 Jan; 1580(1):77-93. PubMed ID: 11923102
[TBL] [Abstract][Full Text] [Related]
40. Intestinal sterol transporters and cholesterol absorption inhibition.
Davis HR; Tershakovec AM; Tomassini JE; Musliner T
Curr Opin Lipidol; 2011 Dec; 22(6):467-78. PubMed ID: 22101558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
